IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature CommunicationsGlobeNewsWire • 12/15/25
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/14/25
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewsWire • 11/07/25
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025GlobeNewsWire • 10/20/25
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025GlobeNewsWire • 09/23/25
IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 09/03/25
IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/14/25
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly MissedGlobeNewsWire • 08/11/25
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaGlobeNewsWire • 08/10/25
IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 05/28/25
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/20/25
IO Biotech Reports First Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 05/14/25
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025GlobeNewsWire • 04/26/25
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170GlobeNewsWire • 04/25/25